Guardant Health, Inc., a prominent company in the field of precision oncology, has established a multi-year global strategic collaboration with Merck, known as MSD outside the United States and Canada, to harness the benefits of Guardant’s liquid and tissue biopsy portfolio and Guardant Infinity™ Smart platform in association with the development and commercialization of Merck’s portfolio of oncology treatments across the global arena. As a part of the deal, patients will be enrolled for Merck’s global studies using Guardant’s portfolio of assays, identify opportunities for development of new treatments using Guardant’s liquid biopsies as companions for these treatments, along with commercialization activities for treatments and companions across the US, Asia-Pacific, UK, and EU regions. “This strategic collaboration allows us to bring the power of the Infinity Smart platform to some of the most important oncology programs in development today,” said Helmy Eltoukhy, Guardant Health chairman and co-CEO. “As biomarkers become more central to therapy selection, our goal is to ensure that every trial has the molecular clarity needed to reach the right patients. This collaboration strengthens our shared commitment to rigor, scale, and faster development of life-changing cancer therapies.”
Also Read: InterAx and Alveus Forge Strategic Partnership to Advance Metabolic Disease Therapeutics
This collaboration reinforces Guardant Health’s precision oncology strategy by broadening access to its highly specialized blood and tissue tests, real-world data insights, and artificial intelligence analysis capabilities in oncology for better patient outcomes from the earlier stages of disease identification to therapy evaluation and management. Guardant tests can also assist in improving clinical trials by facilitating molecular characterization and supporting complementary diagnostics that have the potential for rapid regulatory approvals for new targeted therapies. With Guardant Health’s capability in specialized tests and potential complementary diagnostics that have the potential for rapid regulatory approvals in new therapies and Merck’s oncology research expertise and worldwide footprint, this collaboration also has the potential for new oncology therapies from research development stages to reach patients more quickly than ever before, which can be attributed to the new biopharma shift towards collaborative innovation development of diagnostics and therapeutics.